Venture capital fund · 1 deal
Investment firm backing healthcare businesses
Sydney, NSW
Every published round Genesis Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Ochre Health | Unnamed stage | 7 Oct 2025 | - | Participant | Genesis Capital portfolio, Genesis Capital portfolio |
Companies Genesis Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Ochre Health | 7 Oct 2025 | 1 | 0 |
Companies Genesis Capital's own portfolio page lists that no published round yet places it in. The page is the source; the round is being looked for.
| Company | Site |
|---|---|
| Agilex Biolabs | - |
| Avance Clinical | - |
| Avina | - |
| Crux Biolabs | - |
| Evaris Pharma | - |
| HealthBright | - |
| Investor Portal | auth.au.ansarada.com ↗ |
| LifeCare | - |
| Momentum Clinical Research | - |
| Pacific Smiles | - |
| Sana Health Group | - |
| SmartClinics | - |
| Syntro Health | - |
Fund closes reported for Genesis Capital, as distinct from the investments it has made.
Companies Genesis Capital has backed that another company then bought. An exit for the holding, not a deal Genesis Capital did.
Stories naming Genesis Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Venture firm Genesis Capital's post responds to AFR coverage by describing its new backing of rural primary-care operator Ochre Health and its confidence in Australian primary care.
Genesis Capital says its role at Pacific Smiles Group has grown, with the investor set to take most seats on the dental operator's board.
Genesis Capital says the AFR reported its roughly $350 million fundraise, which strengthens its ability to back growth-stage healthcare companies in medical services, diagnostics and care infrastructure.
Genesis Capital's blog post highlights Australian Financial Review coverage of its funding of clinical-trials firm AusTrials, which it says will help expand the company's capabilities and sponsor relationships.
AFR healthcare and fitness section roundup: Early Bird raised $2 million led by Hyper Ventures; Resmed sold MatrixCare; Radiopharm seeks $16 million; plus Mayne Pharma, Healthscope, Sigma and policy stories.
Also SmartCompany